¼¼°èÀÇ ¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀå
Companion Animal Arthritis
»óǰÄÚµå : 1774725
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 465 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¹Ý·Áµ¿¹° °üÀý¿° ¼¼°è ½ÃÀåÀº 2030³â±îÁö 48¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 34¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¹Ý·Áµ¿¹° °üÀý¿° ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 6.0%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 48¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ °³´Â CAGR 6.7%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 29¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °í¾çÀÌ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 5.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 9¾ï 1,510¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀåÀº 2024³â¿¡´Â 9¾ï 1,510¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 9¾ï 7,910¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 9.6%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 2.9%¿Í 6.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¹Ý·Áµ¿¹° °üÀý¿° ȯÀÚ Áõ°¡¸¦ ÁÖµµÇÏ´Â ¿äÀÎÀº ¹«¾ùÀϱî?

¹Ý·Áµ¿¹°, ƯÈ÷ °³¿Í °í¾çÀÌÀÇ °üÀý¿°Àº ¹Ý·Áµ¿¹°ÀÇ ¼ö¸í ¿¬Àå, ºñ¸¸ÀÇ È®»ê, º¸È£ÀÚÀÇ ÀÎ½Ä °³¼± µî ¿©·¯ ¿äÀÎÀ¸·Î ÀÎÇØ Áõ°¡ Ãß¼¼¿¡ ÀÖ½À´Ï´Ù. ¼öÀÇÇÐÀÇ ¹ßÀü°ú Áø´Ü ´É·ÂÀÇ Çâ»óÀ¸·Î ÀÎÇØ °üÀý¿°À» ¹ß°ßÇÏÁö ¸øÇßÀ» ¼öµµ ÀÖ´Â °üÀý¿°À» ¹ß°ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ´õ ¸¹Àº °¡Á¤ÀÌ ¹Ý·Áµ¿¹°À» °¡Á·ÀÇ ÀÏ¿øÀ¸·Î ¿©±â°Ô µÇ¸é¼­ °üÀý¿° °ü¸® ¼Ö·ç¼ÇÀ» Æ÷ÇÔÇÑ °íǰÁú ¼öÀÇÇÐÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çß½À´Ï´Ù. ¶ÇÇÑ, ¹Ý·Áµ¿¹°ÀÇ ³ë·É Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó °üÀý¿° °ü¸®°¡ ¼öÀÇÇÐÀÇ ÃÖÀü¼±¿¡ ³õÀÌ°Ô µÇ¾ú½À´Ï´Ù. ¸¹Àº º¸È£ÀÚµéÀº ÇöÀç ÀüÅë ÀǾàǰ¿¡¼­ Àüü·ÐÀû Ä¡·á±îÁö ´Ù¾çÇÑ Ä¡·á¹ýÀ» Àû±ØÀûÀ¸·Î ã°í ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹° º¸ÇèÀÇ º¸Àå¹üÀ§ È®´ë´Â ¹Ý·Áµ¿¹° º¸È£ÀÚµéÀÇ °æÁ¦Àû À庮À» ³·Ãß°í °üÀý¿° Ä¡·á¸¦ º¸´Ù ½±°Ô Á¢ÇÒ ¼ö ÀÖµµ·Ï Çß½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ¹Ý·Áµ¿¹°ÀÇ °ñ°üÀý¿° ¹× ÅðÇ༺ °üÀý ÁúȯÀ» °ü¸®Çϱâ À§ÇÑ »õ·Ó°í °³¼±µÈ Ä¡·á¹ýÀ» °³¹ßÇÏ´Â ±â¾÷µé¿¡ ÀÇÇØ ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¼öÀÇÇÐ ºÐ¾ßÀÇ ±â¼ú Çõ½ÅÀº °üÀý¿° Ä¡·á¸¦ ¾î¶»°Ô º¯È­½Ã۰í ÀÖÀ»±î?

¼öÀÇÇÐÀº °üÀý¿° Ä¡·á¿¡ ÀÖ¾î Å« ÁøÀüÀ» º¸À̰í ÀÖÀ¸¸ç, º¸´Ù Á¤±³ÇÏ°í º¹ÇÕÀûÀÎ Á¢±Ù¹æ½ÄÀ¸·Î ÀüȯÇϰí ÀÖ½À´Ï´Ù. ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦(NSAIDs)°¡ ¿©ÀüÈ÷ ÁÖ¿ä Ä¡·á ¿É¼ÇÀÌÁö¸¸, Áٱ⼼Æ÷ Ä¡·á¿Í Ç÷¼ÒÆÇdzºÎÇ÷Àå(PRP) Ä¡·á¸¦ Æ÷ÇÔÇÑ Àç»ýÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀº NSAIDsÀÇ Àå±â »ç¿ëÀ¸·Î ÀÎÇÑ ºÎÀÛ¿ë ¾øÀÌ ¼Õ»óµÈ Á¶Á÷À» º¹±¸Çϰí À̵¿¼ºÀ» °³¼±ÇÒ ¼ö ÀÖ´Ù´Â Á¡¿¡¼­ ¸¹Àº ÁöÁö¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. °üÀý¿° µ¿¹°ÀÇ ÅëÁõ ¼ö¿ëü¸¦ Ÿ°ÙÀ¸·Î Ưº°È÷ ¼³°èµÈ ´ÜŬ·ÐÇ×üÀÇ µµÀÔÀº ½ÃÀå¿¡¼­ ¶Ç ´Ù¸¥ Áß¿äÇÑ ÀÌÁ¤Ç¥ÀÔ´Ï´Ù. ÀÌ »õ·Î¿î »ý¹°ÇÐÀû Á¦Á¦´Â ±âÁ¸ ÅëÁõ °ü¸® ¹æ¹ý¿¡ ºñÇØ ºÎÀÛ¿ëÀÌ Àû°í Àå±â°£ ÅëÁõ ¿ÏÈ­¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ¿À¸Þ°¡ 3 Áö¹æ»ê, ±Û·çÄÚ»ç¹Î, Äܵå·ÎÀÌÆ¾ º¸ÃæÁ¦¸¦ Æ÷ÇÔÇÑ ¿µ¾ç º¸ÃæÁ¦ÀÇ ¹ßÀüÀº °üÀý¿° °ü¸® ºÎ¹®ÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¦Á¶¾÷üµéÀº ÇöÀç ¹Ý·Áµ¿¹°ÀÇ ¼øÀÀµµ¸¦ ³ôÀ̰í ÃÖÀûÀÇ Ä¡·á È¿°ú¸¦ º¸ÀåÇϱâ À§ÇØ ¼±È£µµ°¡ ³ôÀº Á¦Çü °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù.

ºñ¾à¹° ¿ä¹ýÀÌ ±ÞÁõÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

ÀǾàǰÀÇ Àå±â »ç¿ë¿¡ ´ëÇÑ ¿ì·Á°¡ Ä¿Áö¸é¼­ ¹Ý·Áµ¿¹° º¸È£ÀÚ¿Í ¼öÀÇ»ç ¸ðµÎ °üÀý¿° °ü¸®¸¦ À§ÇÑ ºñ¾à¹°Àû °³ÀÔ¿¡ Á¡Á¡ ´õ ¸¹Àº °ü½ÉÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ¼öÄ¡·á, ħ¼ú, Ä¡·á¿ë ·¹ÀÌÀú´Â À̵¿¼ºÀ» ³ôÀÌ°í ºÒÆíÇÔÀ» ÁÙÀ̱â À§ÇÑ º¸¿ÏÀûÀÎ Ä¡·á¹ýÀ¸·Î ³Î¸® ¹Þ¾Æµé¿©Áö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù¹ýÀº ¾à¹° ¾ø´Â ´ëü ¿ä¹ýÀ» ¿øÇÏ´Â º¸È£ÀÚ³ª ÃÖ´ëÇÑÀÇ È¿°ú¸¦ ¾ò±â À§ÇØ ¿©·¯ °¡Áö Ä¡·á¹ýÀ» Á¶ÇÕÇϰíÀÚ ÇÏ´Â º¸È£ÀÚµé »çÀÌ¿¡¼­ ƯÈ÷ ÀαⰡ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹Ý·Áµ¿¹° ¿þ¾î·¯ºí ±â¼úÀÇ ¹ßÀüÀº ¿îµ¿ ´É·ÂÀ» ¸ð´ÏÅ͸µÇÏ°í °üÀý ±â´É ÀúÇϸ¦ Á¶±â¿¡ ¹ß°ßÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, AI ±â¹Ý ºÐ¼® ±â´ÉÀ» °®Ãá ½º¸¶Æ® ¸ñ°ÉÀÌ¿Í È°µ¿ ¸ð´ÏÅÍ´Â ¼öÀÇ»ç¿Í º¸È£ÀÚ°¡ °üÀý¿° °ü¸®¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ °áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀ̼ÇÀ» ÅëÇÑ °¡ÀÌµå ¹°¸®Ä¡·á ¼¼¼ÇÀ» Æ÷ÇÔÇÑ ÀçÅà ÀçȰ ÇÁ·Î±×·¥ÀÇ °¡¿ë¼ºÀº °üÀý¿° Ä¡·á¸¦ º¸´Ù Ä£¼÷ÇÏ°í °³º°È­ÇÏ¿© °üÀý¿° °ü¸®¸¦ ´õ¿í Ä£¼÷ÇÏ°í °³º°È­ÇÒ ¼ö ÀÖ´Â ¶Ç ´Ù¸¥ »õ·Î¿î Æ®·»µåÀÔ´Ï´Ù.

½ÃÀå È®´ë¸¦ ÃËÁøÇÏ´Â ÁÖ¿ä ¼ºÀå ¿äÀÎÀº ¹«¾ùÀΰ¡?

¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀåÀÇ ¼ºÀåÀº ¹Ý·Áµ¿¹°ÀÇ °í·ÉÈ­, ¹Ý·Áµ¿¹°ÀÇ Àΰ£È­, °üÀý¿° Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀÎ½Ä È®´ë µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÇÁ¸®¹Ì¾ö ÆêÄɾ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¼öÀÇÇÐ ¼­ºñ½º, ÀǾàǰ, ´ëü ¿ä¹ý¿¡ ´ëÇÑ ÁöÃâÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àü¹® µ¿¹°º´¿ø°ú ÀçȰ¼¾ÅÍÀÇ Áõ°¡´Â °í±Þ °üÀý¿° Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼º ¹× äÅÿ¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ »ý¹°ÇÐÀû Á¦Á¦ ¹× Àç»ýÀÇ·á ºÐ¾ßÀÇ ±â¼ú Çõ½ÅÀº ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. º¸´Ù ¾ÈÀüÇϰí È¿°úÀûÀÎ Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇØ ¿¬±¸°³¹ß¿¡ ÅõÀÚÇÏ´Â ±â¾÷µéÀº ½ÃÀå ħÅõ¸¦ °­·ÂÇÏ°Ô º¸°í ÀÖ½À´Ï´Ù. °üÀý¿° Ä¡·áºñ¸¦ º¸ÀåÇÏ´Â ¹Ý·Áµ¿¹° º¸ÇèÀÇ º¸±ÞÀº ¹Ý·Áµ¿¹° º¸È£Àڵ鿡°Ô µ¿¹° ÀÇ·áÀÇ °æÁ¦¼ºÀ» ³ô¿© °í±Þ Ä¡·á¿¡ ´ëÇÑ ÁöÃâÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àüü·ÐÀû, ÀÚ¿¬Àû, ¿¹¹æÀû °Ç°­°ü¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼±È£µµ°¡ Áõ°¡Çϸ鼭 ÁøÈ­ÇÏ´Â ¼ÒºñÀÚ ÇൿÀº °üÀý¿° Ä¡·áÀÇ ÁöÇüÀ» À籸¼ºÇϰí ÀÖ½À´Ï´Ù. Á¦Á¶¾÷üµéÀº Çõ½ÅÀûÀÎ °Ç°­º¸Á¶½Äǰ, ±â´É¼º ½Äǰ ¹× ÀÌ·¯ÇÑ ¼ö¿ä¸¦ ÃæÁ·½Ã۱â À§ÇØ Á¶Á¤µÈ »õ·Î¿î Á¦ÇüÀ» µµÀÔÇÏ¿© ÀÌ¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹° °üÀý¿°¿¡ ´ëÇÑ ÀνÄÀÌ °è¼Ó ³ô¾ÆÁö°í Ä¡·á ¿É¼ÇÀÌ ´õ¿í Á¤±³ÇØÁü¿¡ µû¶ó ¹Ý·Áµ¿¹° °üÀý¿° ½ÃÀåÀº ÇâÈÄ ¸î ³â µ¿¾È Áö¼ÓÀûÀÎ ¼ºÀåÀ» ÀÌ·ê Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

ºÎ¹®

µ¿¹° À¯Çü(°³, °í¾çÀÌ, ±âŸ µ¿¹° À¯Çü), ÀûÀÀÁõ(°ñ°üÀý¿° ÀûÀÀÁõ, ±âŸ ÀûÀÀÁõ), Ä¡·á À¯Çü(Åõ¾à Ä¡·á, º¸ÃæÁ¦ Ä¡·á, ±âŸ Ä¡·á À¯Çü), À¯Åë ä³Î(µ¿¹° º´¿ø¡¤Å¬¸®´Ð À¯Åë ä³Î, ¿Â¶óÀÎ ½ºÅä¾î À¯Åë ä³Î, ¼Ò¸Å ¾à±¹ À¯Åë ä³Î, ±âŸ À¯Åë ä³Î)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Companion Animal Arthritis Market to Reach US$4.8 Billion by 2030

The global market for Companion Animal Arthritis estimated at US$3.4 Billion in the year 2024, is expected to reach US$4.8 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Dogs, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Cats segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$915.1 Million While China is Forecast to Grow at 9.6% CAGR

The Companion Animal Arthritis market in the U.S. is estimated at US$915.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$979.1 Million by the year 2030 trailing a CAGR of 9.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Companion Animal Arthritis Market - Key Trends & Drivers Summarized

What is Driving the Rise in Companion Animal Arthritis Cases?

Arthritis in companion animals, particularly dogs and cats, has been on the rise due to several factors, including increased pet longevity, obesity prevalence, and greater awareness among pet owners. Veterinary advancements and improved diagnostic capabilities have contributed to the identification of arthritis cases that might have otherwise gone unnoticed. As more households treat pets as family members, the demand for high-quality veterinary care, including arthritis management solutions, has surged significantly. Additionally, the growing geriatric pet population has placed arthritis management at the forefront of veterinary care. Many pet owners are now proactively seeking treatments ranging from traditional pharmaceuticals to holistic therapies. The expansion of companion animal insurance coverage has also made arthritis treatments more accessible, reducing financial barriers for pet owners. This trend is fueling the market’s growth, as companies develop new and improved treatment options for managing osteoarthritis and degenerative joint diseases in pets.

How Are Innovations in Veterinary Medicine Transforming Arthritis Treatment?

Veterinary medicine has seen significant breakthroughs in arthritis treatment, with a shift toward more sophisticated, multi-modal approaches. Non-steroidal anti-inflammatory drugs (NSAIDs) remain a primary treatment option, but there is increasing interest in regenerative medicine, including stem cell therapy and platelet-rich plasma (PRP) treatments. These therapies are gaining traction due to their potential to repair damaged tissues and improve mobility without the side effects associated with long-term NSAID use. The introduction of monoclonal antibodies specifically designed to target pain receptors in arthritic animals marks another significant milestone in the market. These novel biologics offer extended pain relief with fewer adverse reactions compared to traditional pain management methods. Additionally, advancements in nutraceuticals, including omega-3 fatty acids, glucosamine, and chondroitin supplements, are driving growth in the arthritis management segment. Manufacturers are now focusing on developing palatable formulations that encourage compliance among pet owners and ensure optimal therapeutic benefits.

Why Is the Market Seeing a Surge in Non-Pharmaceutical Therapies?

As concerns grow over the long-term use of pharmaceuticals, pet owners and veterinarians alike are increasingly turning to non-pharmaceutical interventions for arthritis management. Hydrotherapy, acupuncture, and therapeutic laser treatments are gaining widespread acceptance as complementary therapies that enhance mobility and reduce discomfort. These approaches are especially popular among owners who seek drug-free alternatives or wish to combine treatments for maximum effectiveness. Furthermore, advancements in wearable technology for pets are playing a crucial role in monitoring mobility and detecting early signs of joint deterioration. Smart collars and activity monitors equipped with AI-driven analytics help veterinarians and pet owners make informed decisions about arthritis management. The availability of home-based rehabilitation programs, including guided physiotherapy sessions via mobile applications, is another emerging trend, making arthritis care more accessible and personalized.

What Are the Key Growth Drivers Fueling Market Expansion?

The growth in the Companion Animal Arthritis market is driven by several factors, including the rising number of aging pets, increased pet humanization, and expanding awareness of arthritis treatment options. The rising trend of premium pet care has led to higher spending on veterinary services, pharmaceuticals, and alternative therapies. Additionally, the growing presence of specialized veterinary clinics and rehabilitation centers is contributing to the accessibility and adoption of advanced arthritis treatments. Technological innovations, particularly in biologics and regenerative medicine, are further propelling market expansion. Companies investing in research and development to create safer and more effective treatment options are seeing strong market penetration. The increasing acceptance of pet insurance, which often covers arthritis treatment costs, is making veterinary care more affordable for pet owners, encouraging higher spending on advanced therapies. Moreover, evolving consumer behavior-marked by an increasing preference for holistic, natural, and preventative healthcare solutions-is reshaping the arthritis treatment landscape. Manufacturers are responding by introducing innovative dietary supplements, functional foods, and novel drug formulations tailored to meet these demands. As awareness continues to grow and treatment options become more sophisticated, the Companion Animal Arthritis market is poised for sustained growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Companion Animal Arthritis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Animal Type (Dogs, Cats, Other Animal Types); Indication (Osteoarthritis Indication, Other Indications); Treatment Type (Medications Treatment, Supplements Treatment, Other Treatment Types); Distribution Channel (Veterinary Hospitals and Clinics Distribution Channel, Online Stores Distribution Channel, Retail Pharmacies Distribution Channel, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â